|
QST Consultations, Ltd. Chooses OmniComm Systems, Inc. For Electronic Data Capture
(EDC) In A Top 15 Pharmaceutical, Phase IV Clinical Trial
OmniComm's CRO Preferred Program™ partner chooses the TrialMaster EDC solution
for a Phase IV, multi-site international allergy study
FT. LAUDERDALE, FL - December 13, 2007 - /MarketWire/ - OmniComm Systems, Inc. (OTC
Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions
for clinical trials, today announced that QST Consultations, Ltd. has selected OmniComm's
integrated EDC solution, TrialMasterTM, for a Phase IV, multi-site international
allergy study. QST is a Contract Research Organization (CRO) that provides clinical
trial support for the pharmaceutical and medical device industries. QST has successfully
used TrialMaster for EDC clinical trial support in the past and has recently joined
OmniComm's CRO Preferred Program.
"QST's clients range from small start-ups to large major pharmaceutical companies
that conduct complex clinical studies and they all expect and deserve a superior
level of personalized service, technical expertise and quality deliverables. We
have selected OmniComm as our partner to provide EDC because having worked with
them in the past we knew that they were a good match to satisfy our clients' expectations,"
said John Quiring, Ph.D., President of QST Consultations. "It is important for us
to use a full service EDC provider whose capabilities include both a strong technology
product and support services that complement our own efforts."
QST Consultations, Ltd. is an independent consulting firm that specializes in clinical
study design, protocol development, CRF design, data management, biostatistical
analysis, report writing services and statistical consultation services for the
medical device and pharmaceutical industries. QST Consultations has been involved
in many successful Phase I through Phase IV clinical trials in support of 510 (k),
PMA, ANDA, and NDA submissions. QST's primary focus is to meet the goals of each
client through personalized service and technical expertise. QST Consultations,
Ltd. was founded in 1974 and incorporated in 1985.
"It gives us great satisfaction to know that QST has chosen TrialMaster with confidence
for their EDC needs for this important clinical trial. At OmniComm, we are diligent
about delivering solutions that exceed expectations for all of our customers and
it is proof positive that we are delivering superior solutions as promised when
important clients like QST choose us for repeat business," said Stephen Johnson,
Executive Vice President of Business Development, Professional Services and Client
Services and Support.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions
to pharmaceutical, biotechnology, research and medical device organizations that
conduct life changing clinical trial research. OmniComm's growing base of satisfied
customers is a direct result of the company's commitment to deliver products and
services that ensure ease of use, faster study build, ease of integration and better
performance. OmniComm's client intuitive pricing model allows companies that range
from small to mid-size to large scale institutions to safely and efficiently capitalize
on their clinical research investments.
OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies
in North America during the last 5 years. OmniComm Systems, Inc. has corporate headquarters
in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California,
Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm's future expectations, including without limitation, future
revenues and earnings, plans and objectives for the future operations, future agreements,
future economic performance, operations and all other statements in this press release
other than historical facts are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities Litigation Reform
Act of 1995. OmniComm intends that such forward-looking statements be subject to
the Safe Harbors created thereby. Since these statements involve risks and uncertainties,
including but not limited to economic competitive, governmental, contractual and
technological factors affecting OmniComm's operations, markets and profitability,
actual results could differ materially and adversely from the expected results.
CONTACT:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283
lkelley@omnicomm.com
Back
|
